Novo er jo sikker havn so mman siger.
den er godt nok faldet, men ikke noget der skræmmer mig.
Ligger omkring 400 hvad den vel også gjorde slut 2019.
Men hvor får Novo deres råvarer fra?
kan de blive ramt der?
den er godt nok faldet, men ikke noget der skræmmer mig.
Ligger omkring 400 hvad den vel også gjorde slut 2019.
Men hvor får Novo deres råvarer fra?
kan de blive ramt der?
15/3 2020 22:29 tommycarstensen 0
82752 koden Jeg tror ikke, at vi kommer til at se karantæner, der varer mere end 2-3 uger. Til trods for karantæner, vil der sandsynligvis stadig blive produceret toilet-papir og anti-diabetika.
Halting China's Economy Was Hard. Restarting It Is Harder.
https://www.nytimes.com/2020/03/12/business/china-coronavirus-economy.html
https://www.sec.gov/Archives/edgar/data/353278/000162828020001021/novo-b20xf12x31x19.htm
Our financial and operating performance may be adversely affected by epidemics or other public health crises.
Our financial and operating performance could be materially and adversely affected by the outbreak of epidemics or other public health crises. For example, in late December 2019 a notice of pneumonia of unknown cause originating from Wuhan, Hubei province was reported to the World Health Organisation. A novel coronavirus (nCoV) was identified, with cases soon confirmed in multiple provinces in China, as well as in other countries. The Chinese government has placed Wuhan and multiple other cities in Hubei province under quarantine, with approximately 60 million people affected. Local governments in China are also issuing local policies and guidance including with respect to work arrangements after the Chinese New Year holiday, and travel to and from China has been suspended or restricted by certain air carriers and foreign governments.
The risks to the Company of epidemics and other public health crises, such as the on-going novel coronavirus, include risks to employee health and safety, and reduced sales due to fewer promotional activities and less healthcare spending on chronic diseases as resources are diverted to epidemiology management. Our business could also experience a slowdown or temporary suspension in production in geographic locations impacted. Any prolonged restrictive measures put in place in order to control an outbreak of contagious disease or other adverse public health development, in China or any of our targeted markets, may have a material and adverse effect on our business operations.
Halting China's Economy Was Hard. Restarting It Is Harder.
https://www.nytimes.com/2020/03/12/business/china-coronavirus-economy.html
https://www.sec.gov/Archives/edgar/data/353278/000162828020001021/novo-b20xf12x31x19.htm
Our financial and operating performance may be adversely affected by epidemics or other public health crises.
Our financial and operating performance could be materially and adversely affected by the outbreak of epidemics or other public health crises. For example, in late December 2019 a notice of pneumonia of unknown cause originating from Wuhan, Hubei province was reported to the World Health Organisation. A novel coronavirus (nCoV) was identified, with cases soon confirmed in multiple provinces in China, as well as in other countries. The Chinese government has placed Wuhan and multiple other cities in Hubei province under quarantine, with approximately 60 million people affected. Local governments in China are also issuing local policies and guidance including with respect to work arrangements after the Chinese New Year holiday, and travel to and from China has been suspended or restricted by certain air carriers and foreign governments.
The risks to the Company of epidemics and other public health crises, such as the on-going novel coronavirus, include risks to employee health and safety, and reduced sales due to fewer promotional activities and less healthcare spending on chronic diseases as resources are diverted to epidemiology management. Our business could also experience a slowdown or temporary suspension in production in geographic locations impacted. Any prolonged restrictive measures put in place in order to control an outbreak of contagious disease or other adverse public health development, in China or any of our targeted markets, may have a material and adverse effect on our business operations.
16/3 2020 06:45 tommycarstensen 182783 Fra deres aars-rapport:
Failures or delays may occur at production
sites or throughout the extensive global
supply chain, relating to procurement of
ingredients and components as well as
distribution of products. This could be due
to breakdowns or quality failures at company sites or at key suppliers' production
facilities.
If Novo Nordisk were prevented from
supplying products to markets, pharmacies
and hospitals could face product shortages,
with potential implications for patients'
daily treatment needs.
Internal quality audits and annual inspections by regulatory authorities document
GMP compliance, and alternative supply
sites for critical raw materials and back-up
facilities are in place for key production
plants and safety inventories, to prevent and respond to accidents or other
disruptions to supplies. Global production
reduces supply risks.
De har ikke sendt nogen advarsler ud, saa man maa antage, at de ikke forudser, at de loeber ind i problemer.
Failures or delays may occur at production
sites or throughout the extensive global
supply chain, relating to procurement of
ingredients and components as well as
distribution of products. This could be due
to breakdowns or quality failures at company sites or at key suppliers' production
facilities.
If Novo Nordisk were prevented from
supplying products to markets, pharmacies
and hospitals could face product shortages,
with potential implications for patients'
daily treatment needs.
Internal quality audits and annual inspections by regulatory authorities document
GMP compliance, and alternative supply
sites for critical raw materials and back-up
facilities are in place for key production
plants and safety inventories, to prevent and respond to accidents or other
disruptions to supplies. Global production
reduces supply risks.
De har ikke sendt nogen advarsler ud, saa man maa antage, at de ikke forudser, at de loeber ind i problemer.
16/3 2020 16:17 tommycarstensen 082808 Novo Nordisk A/S - Share repurchase programme
http://www.globenewswire.com/news-release/2020/03/16/2001067/0/en/Novo-Nordisk-A-S-Share-repurchase-programme.html
Bagsværd, Denmark, 16 March 2020 - On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.
Since the announcement as of 9 March 2020, the following transactions have been made:
Number of
B shares Average
purchase price Transaction
value, DKK
Accumulated, last announcement 2,550,000 1,091,382,293
9 March 2020 120,000 394.48 47,337,651
10 March 2020 120,000 399.14 47,897,167
11 March 2020 120,000 391.29 46,955,011
12 March 2020 130,000 368.91 47,957,981
13 March 2020 125,000 373.09 46,636,854
Accumulated under the programme 3,165,000 1,328,166,957
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 53,222,884 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 13 March 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 3,165,000 B shares at an average share price of DKK 419.64 per B share equal to a transaction value of DKK 1,328,166,957.
http://www.globenewswire.com/news-release/2020/03/16/2001067/0/en/Novo-Nordisk-A-S-Share-repurchase-programme.html
Bagsværd, Denmark, 16 March 2020 - On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.
Since the announcement as of 9 March 2020, the following transactions have been made:
Number of
B shares Average
purchase price Transaction
value, DKK
Accumulated, last announcement 2,550,000 1,091,382,293
9 March 2020 120,000 394.48 47,337,651
10 March 2020 120,000 399.14 47,897,167
11 March 2020 120,000 391.29 46,955,011
12 March 2020 130,000 368.91 47,957,981
13 March 2020 125,000 373.09 46,636,854
Accumulated under the programme 3,165,000 1,328,166,957
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 53,222,884 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 13 March 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 3,165,000 B shares at an average share price of DKK 419.64 per B share equal to a transaction value of DKK 1,328,166,957.
